Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Declines By 15.2%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a significant drop in short interest in February. As of February 13th, there was short interest totaling 122,516 shares, a drop of 15.2% from the January 29th total of 144,490 shares. Based on an average daily trading volume, of 108,559 shares, the short-interest ratio is presently 1.1 days. Currently, 7.7% of the company’s stock are short sold. Currently, 7.7% of the company’s stock are short sold. Based on an average daily trading volume, of 108,559 shares, the short-interest ratio is presently 1.1 days.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned approximately 1.07% of Cardio Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Stock Down 8.8%

CDIO opened at $4.74 on Wednesday. Cardio Diagnostics has a 12-month low of $0.97 and a 12-month high of $17.39. The firm has a market capitalization of $8.67 million, a P/E ratio of -1.27 and a beta of 2.28. The stock’s 50 day moving average price is $2.42 and its two-hundred day moving average price is $3.26.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Cardio Diagnostics has a consensus rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.